Skip to main content
Log in

Open innovation networks between academia and industry: an imperative for breakthrough therapies

  • Commentary
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: The current model for producing biopharmaceutical innovation is economically unsustainable.
Figure 2: How to manage industry-academic partnerships as one would an investment portfolio.

References

  1. Chesbrough, H.W. Open Innovation: The New Imperative for Creating And Profiting from Technology (Harvard Business School Press, Boston, 2003)

    Google Scholar 

  2. Chesbrough, H.W. Open Business Models: How to Thrive in the New Innovation Landscape (Harvard Business School Press, Boston, 2006)

    Google Scholar 

  3. Jones, A. & Clifford, L. Nat. Rev. Drug Discov. 4, 807–808 (2005).

    Article  CAS  Google Scholar 

  4. Hughes, B. Nat. Rev. Drug Discov. 7, 631–632 (2008).

    Article  CAS  Google Scholar 

  5. Jarvis, L.M. Chem. Eng. News 86, 13–20 (2008).

    Google Scholar 

  6. Phillips, K.A. J. Am. Med. Assoc. 300, 2542–2544 (2008).

    Article  CAS  Google Scholar 

  7. Deverka, P.A., Doksum, T. & Carlson, R.J. Clin. Pharmacol. Ther. 82, 427–434 (2007).

    Article  CAS  Google Scholar 

  8. Wilan, K.H. Cell 129, 847–850 (2007).

    Article  CAS  Google Scholar 

  9. Stossel, T.P. N. Engl. J. Med. 353, 1060–1065 (2005).

    Article  CAS  Google Scholar 

  10. White, A.P. et al. Spine 32, S53–S57 (2007)

    Article  Google Scholar 

  11. Korn, D. J. Am. Med. Assoc. 284, 2234–2237 (2000).

    Article  CAS  Google Scholar 

  12. Brennan, T.A. et al. J. Am. Med. Assoc. 295, 429–433 (2006).

    Article  CAS  Google Scholar 

  13. Gordon, M. & Ertel, D. Point of the Deal: How to Negotiate When Yes Is Not Enough (Harvard Business School Press, Boston, 2007)

    Google Scholar 

  14. Melese, T. Res. Manage. Rev. 15, 13–21 (2006).

    Google Scholar 

  15. Zerhouni, E.A. N. Engl. J. Med. 353, 1621–1623 (2005).

    Article  CAS  Google Scholar 

  16. Carpenter, S. Science 317, 966–967 (2007).

    Article  Google Scholar 

  17. Bernstein, K. BioCentury 14, A1–A5 (2006).

    Google Scholar 

  18. Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).

    Article  CAS  Google Scholar 

  19. Chesbrough, H.W. & Appleyard, M.M. Calif. Manage. Rev. 50, 57–76 (2007).

    Article  Google Scholar 

  20. Travis, J. Science 319, 1750–1752 (2008).

    Article  CAS  Google Scholar 

  21. Nathan, C. Nat. Med. 13, 304–308 (2007).

    Article  CAS  Google Scholar 

  22. Verrils, N.M. Clin. Biochem. Rev. 27, 99–116 (2006).

    Google Scholar 

  23. Blow, N. Nat. Meth. 5, 361–368 (2008).

    Article  CAS  Google Scholar 

  24. Altar, C.A. Clin. Pharmacol. Ther. 83, 361–364 (2008).

    CAS  Google Scholar 

  25. Saxena, R. Science 316, 1331–1336 (2007).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank E. Lium and T. Shen for contributing to the article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Teri Melese.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melese, T., Lin, S., Chang, J. et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 15, 502–507 (2009). https://doi.org/10.1038/nm0509-502

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0509-502

  • Springer Nature America, Inc.

This article is cited by

Navigation